CN112375713A

CN112375713A - Lactobacillus longus SF-B-27 and application thereof

Info

Publication number: CN112375713A
Application number: CN202011342678.XA
Authority: CN
Inventors: 夏越; 马明磊; 刘连军; 耿苗苗; 韩文立; 夏超凡
Original assignee: Shandong Sunflower Bioengineering Co ltd
Current assignee: Shandong Sunflower Bioengineering Co ltd
Priority date: 2020-11-25
Filing date: 2020-11-25
Publication date: 2021-02-19
Anticipated expiration: 2040-11-25
Also published as: CN112375713B

Abstract

The invention relates to the technical field of microorganisms, in particular to lactobacillus longus SF-B-27 and application thereof; the deposit number of the bifidobacterium longum is as follows: CGMCC No. 20925; the bifidobacterium longum SF-B-27 has high adhesion and strong gastrointestinal adaptability, can obviously relieve the sleep problem and increase the sleep time; the product containing the powder of the lactobacillus bifidus SF-B-27 can improve symptoms such as central neurasthenia, insomnia and the like, relieve mental fatigue, inhibit anxiety and depression symptoms and adjust intestinal flora balance by regulating secretion of tryptophan and 5-hydroxytryptamine.

Description

Lactobacillus longus SF-B-27 and application thereof

Technical Field

The invention relates to the technical field of microorganisms, and particularly relates to lactobacillus longus SF-B-27 and application thereof.

Background

According to the definition of 'Chinese adult insomnia diagnosis and treatment guideline', insomnia refers to a subjective experience that a patient does not meet the requirements of sleep time and/or quality and affects daily social functions. The common symptoms of insomnia include difficulty in falling asleep, decreased sleep quality and sleep time, and decreased memory and attention. Along with the development of society, the pressure of people in work and life is getting bigger and bigger, because factors such as living habits and living environments of people influence sleep, the sleep is directly caused to be insufficient, nearly 30 hundred million people suffer from insomnia trouble all over the world at present, 6 hundred million people in China also have the insomnia problem, and the insomnia becomes a huge hidden trouble of the whole society.

At present, the commonly used drugs for treating insomnia are mainly chemical synthesis drugs, such as short-acting drugs of tears such as barbiturates, benzodiazepines and non-benzodiazepines, and although the drugs have definite curative effects, the drugs can cause certain harm to human bodies after long-term use, patients are easy to rely on the drugs, and more likely to cause iatrogenic diseases. Therefore, it is necessary to provide a product which can improve the sleep quality and does not cause drug dependence or adverse reactions.

Disclosure of Invention

Aiming at the technical problem that the prior art lacks a product for improving sleep quality without drug dependence or adverse reaction, the invention provides a lactobacillus longus SF-B-27 and application thereof, wherein the lactobacillus longus SF-B-27 has high adhesion and strong gastrointestinal adaptability, and the product for improving sleep is provided, can obviously relieve the sleep problem and increase the sleep time.

In a first aspect, the invention provides a strain of lactobacillus longus SF-B-27, wherein the lactobacillus longus SF-B-27 has been deposited in China general microbiological culture Collection center (CGMCC) under No. 10/21 in 2020 with the preservation number: CGMCC No. 20925; and (4) storage address: xilu No. 1, Beijing, Chaoyang, Beijing, and institute for microbiology, China academy of sciences.

Further, the Lactobacillus longus SF-B-27 is isolated from feces of healthy infants.

Further, the Lactobacillus longus SF-B-27 has the following characteristics:

(1) morphological characteristics: it is gram-positive, does not form spores and does not move. A rod-like body having a cell size of about 0.5 to 1.3. mu. m.times.1.5 to 8 μm and little change in appearance, wherein the strain is generally characterized by a stick-like shape, being single-grown, paired, or sometimes chained;

(2) colony characteristics: the strain forms obvious bacterial colonies after being subjected to streak culture for 48 hours on an MRS culture medium containing 0.1 percent of L-cysteine hydrochloride, the diameter of the colony is between 0.1 and 2.5mm, and the colony is round, convex, milky white or white, opaque, smooth and soft in surface and free from forming mycelium. The shape of the deep bacterial colony in the culture medium is indefinite by the pouring method, and most of the deep bacterial colony is flat and oval;

(3) growth characteristics: the optimal growth temperature of the strain is 37 ℃, and the strain grows well at the temperature of 36-38 ℃. The optimum initial pH is 6.6-7.0, the anaerobic culture in the culture solution containing glucose has good growth, the liquid tube is in turbid state after 20h culture, i.e. the liquid tube enters the late logarithmic phase or the early stationary phase.

In a second aspect, the present invention provides a use of Lactobacillus longus SF-B-27 as described above for improving sleep.

In a third aspect, the present invention provides a sleep improving product comprising powder of Lactobacillus longus SF-B-27.

Further, the preparation method of the lactobacillus bifidus SF-B-27 bacterial powder comprises the following steps: inoculating bifidobacterium longum SF-B-27 into an MRS liquid culture medium, wherein the inoculation amount is 1%, and after culturing at 37 ℃, centrifuging and carrying out vacuum freeze drying on MRS zymogen liquid to obtain bacterial powder.

Further, the content of the bifidobacterium longum SF-B-27 in the product is 100-500 hundred million/g; furthermore, the content of Bifidobacterium longum SF-B-27 in the product is 100 hundred million/g, 200 hundred million/g or 500 hundred million/g.

Furthermore, the product also comprises auxiliary materials, and the mass ratio of the lactobacillus bifidus SF-B-27 to the auxiliary materials is 1: 100.

Furthermore, the auxiliary materials are any three or any five of red date, astragalus powder, codonopsis pilosula powder, gastrodia elata powder, isomaltooligosaccharide, fructo-oligosaccharide and medlar powder, wherein the isomaltooligosaccharide and the fructo-oligosaccharide are not selected at the same time.

Further, when the auxiliary materials are any three of red date, astragalus powder, codonopsis pilosula powder, gastrodia elata powder, isomaltooligosaccharide, fructo-oligosaccharide and wolfberry powder, the mass ratio of the three auxiliary materials is 1:1:1, and when the auxiliary materials are any five of red date, astragalus powder, codonopsis pilosula powder, gastrodia elata powder, isomaltooligosaccharide, fructo-oligosaccharide and wolfberry powder, the mass ratio of the five auxiliary materials is 1:1:1: 1.

The action mechanism of each auxiliary material is as follows:

red dates: sweet in taste, warm in nature, and capable of entering spleen and stomach channels, and has the functions of tonifying middle-jiao and Qi, nourishing blood and tranquilization and moderating drug property; modern pharmacology finds that the red dates contain rich nutritional ingredients such as proteins, saccharides, organic acids, vitamin A, vitamin C, various trace calcium, amino acids and the like.

Astragalus root: sweet in flavor and slightly warm in nature; it enters spleen and lung meridians. Tonify qi, strengthen superficies, expel toxin, expel pus, induce diuresis, and promote granulation.

Codonopsis pilosula: sweet and neutral. Tonify middle-jiao and Qi, harmonize stomach and promote fluid production, dispel phlegm and relieve cough. Can be used for treating spleen deficiency, anorexia, loose stool, myasthenia of limbs, palpitation, short breath, and dry mouth.

Gastrodia elata: sweet in taste and neutral in nature; it enters liver meridian. Has effects of calming endogenous wind, relieving spasm, suppressing liver yang, dispelling pathogenic wind, and dredging collaterals. It can be used for treating stirring of liver-wind, convulsive epilepsy, convulsion, vertigo, headache, numbness of limbs, hemiplegia, and rheumatalgia.

Medlar: nourish kidney, moisten lung, tonify liver, improve vision. It is indicated for liver and kidney yin deficiency, soreness and weakness of waist and knees, dizziness, blurred vision, hyperdacryosis, cough due to asthenia, diabetes, and spermatorrhea.

The beneficial effect of the invention is that,

(1) the bifidobacterium longum SF-B-27 provided by the invention has high adhesion and strong gastrointestinal adaptability, can obviously relieve the sleep problem and increase the sleep time;

(2) the product for improving sleep provided by the invention can improve symptoms such as central neurasthenia, insomnia and the like by regulating the secretion of tryptophan and 5-hydroxytryptamine; relieving mental fatigue, inhibiting anxiety and depression symptoms, and regulating intestinal flora balance.

Drawings

FIG. 1 is a graph comparing the prolongation of the sleep time of pentobarbital sodium in mice in test example 3;

FIG. 2 is a graph comparing the tryptophan content in blood of mice in test example 3;

FIG. 3 is a graph showing a comparison of the 5-hydroxytryptamine content in blood of mice in test example 3.

Detailed Description

In order to make those skilled in the art better understand the technical solutions in the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Biological material preservation instructions

Classification nomenclature of biological materials: bifidobacterium longum (Bifidobacterium longum)

Bacterial strain designation of biological material: SF-B-27

Deposit name of biological material: china general microbiological culture Collection center

The preservation unit of the biological material is abbreviated as: CGMCC (China general microbiological culture Collection center)

Deposit unit address of biological material: west road No. 1, north west of the township, beijing, ministry of sciences, china, institute of microbiology, zip code: 100101

Preservation date of biological material: no. 10/21 in 2020

Accession number to the collection of biological materials: CGMCC No.20925

Example 1 isolation and characterization of Bifidobacterium longum SF-B-27

1. Bacterial source

Feces of healthy infants.

2. Isolation of the Strain

Ten times of gradient dilution is carried out on a healthy infant feces sample, 100 mu L of each gradient is uniformly coated on an MRS solid plate culture medium, and then the gradient is taken out and placed in an anaerobic tank to carry out anaerobic culture at 37 ℃ overnight;

the MRS solid plate culture medium comprises the following components:

10g of peptone, 5g of beef powder, 4g of yeast powder and K₂HPO₄·7H₂O2g, triammonium citrate 2g, glucose 20g, CH₃COONa·3H₂O5g、MgSO₄·7H₂O0.2g、MnSO₄·4H₂0.05g of O, 801mL of Tween and 1000mL of distilled water;

the next day, colonies with different shapes and sizes grow on the plate, a plurality of characteristic colonies of lactic acid bacteria are selected for the second-generation streak purification treatment, the plate is subjected to anaerobic activation for 1 day to obtain a culture, and then the strain identification is carried out.

3. Identification of Bifidobacterium longum SF-B-27

(1) Identification unit

Biometrics (Shanghai) Ltd.

(2) Primer sequences

27F：5'-AGAGTTTGATCMTGGCTCAG-3'；

1492R：5'-GGTTACCTTGTTACGACTT-3'。

(3) Identified sequences

TGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCGACCTGCCCCATACACCGG AATAGCTCCTGGAAACGGGTGGTAATGCCGGATGCTCCAGTTGATCGCATGGTCTTCTGG GAAAGCTTTCGCGGTATGGGATGGGGTCGCGTCCTATCAGCTTGACGGCGGGGTAACGG CCCACCGTGGCTTCGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACATTGGGACTG AGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCA AGCCTGATGCAGCGACGCCGCGTGAGGGATGGAGGCCTTCGGGTTGTAAACCTCTTTTA TCGGGGAGCAAGCGAGAGTGAGTTTACCCGTTGAATAAGCACCGGCTAACTACGTGCC AGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAAAGGGC TCGTAGGCGGTTCGTCGCGTCCGGTGTGAAAGTCCATCGCTTAACGGTGGATCCGCGCC GGGTACGGGCGGGCTTGAGTGCGGTAGGGGAGACTGGAATTCCCGGTGTAACGGTGGA ATGTGTAGATATCGGGAAGAACACCAATGGCGAAGGCAGGTCTCTGGGCCGTTACTGAC GCTGAGGAGCGAAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCC GTAACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCGTGTCGGAGCTAACGCG TTAAGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGAAATTGACGGG GGCCCGCACAAGCGGCGGAGCATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCT GGGCTTGACATGTTCCCGACGGTCGTAGAGATACGGCTTCCCTTCGGGGCGGGTTCACA GGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGA GCGCAACCCTCGCCCCGTGTTGCCAGCGGATTATGCCGGGAACTCACGGGGGACCGCC GGGGTTAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCTTACGTCCAGG GCTTCACGCATGCTACAATGGCCGGTACAACGGGATGCGACGCGGCGACGCGGAGCGG ATCCCTGAAAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGG AGTCGCTAGTAATCGCGAATCAGCAACGTCGCGGTGAATGCGTTCCCGGGCCTTGTACA CACCGCCCGTCAAGTCATGAAAGTGGGCAGCACCCGAAGCCGGTGGCCTAACCCCTTG TGGGATGGAGCCGTCTAAGGTGAGGCT

(4) Identification results

This strain was identified as Bifidobacterium (Bifidobacterium longum) and was presumed to be Bifidobacterium longum. The classification unit is as follows: (ii) Bacteria; actinobacteria; bifidobacteria; bifidobacterium; a Bifidobacterium.

Example 2A product rich in Bifidobacterium longum SF-B-27 for improving sleep

A product rich in Bifidobacterium longum SF-B-27 for improving sleep comprises Bifidobacterium longum SF-B-27, fructus Jujubae powder, radix astragali powder, radix Codonopsis powder, rhizoma Gastrodiae powder, and isomaltooligosaccharide, wherein the content of Bifidobacterium longum SF-B-27 is 200 hundred million/g.

The preparation method of the product comprises the following steps:

(1) inoculating bifidobacterium longum SF-B-27 into an MRS culture medium plate, wherein the inoculation amount is 1%, and after culturing at 37 ℃, centrifuging and carrying out vacuum freeze drying on MRS bacterial liquid to obtain bacterial powder;

(2) the auxiliary materials are red date powder, astragalus powder, codonopsis pilosula powder, gastrodia elata powder and isomaltooligosaccharide which are compounded according to the proportion of 1:1:1:1:1 to obtain the product.

(3) And (3) mixing the bifidobacterium longum SF-B-27 powder prepared in the step (1) with the auxiliary materials in the step (2) according to the proportion of 1:100 to prepare the product.

Comparative example 1A product for improving sleep

A product for improving sleep is prepared from red date powder, radix astragali powder, radix Codonopsis powder, rhizoma Gastrodiae powder, and isomaltooligosaccharide by mixing at a mass ratio of 1:1:1:1: 1.

Test example 1 Bifidobacterium longum SF-B-27 adhesion Property test

This experiment was performed by testing the Bifidobacterium longum strain SF-B-27 obtained in example 2 for its ability to adhere to extracellular mechanisms.

Inoculating Bifidobacterium longum strain SF-B-27 into MRS liquid culture medium at 1%, culturing at 37 deg.C for 12-14 hr, centrifuging at 8000r/min for 15 min, removing supernatant, collecting precipitate, mixing with RPMI-1640 cell culture medium to reach concentration of 10⁸CFU/mL. The prepared bacterial suspension was added to a 24-well plate at 1ml per well, and the 24-well plate was incubated in 5% CO₂95% CO in air₂Culturing at 37 deg.C for 3 hr in incubator, absorbing non-adhesive bacterial suspension, washing with phosphate buffer salt for 5 times, adding phosphate buffer solution containing polyethylene glycol octyl phenyl ether to dissolve cells, and dissolving with sterile water. And finally counting, wherein the culture condition is constant-temperature anaerobic culture at 37 ℃, and counting the number of viable bacteria after 2-3 days (detection by the GB4789.35 method).

The comparative strains were: FB-01, FB-02 and BB12, wherein BB12 is a standard product of Bifidobacterium strains with high adhesion recognized in the industry, and the strains are all derived from an open strain depository and can be purchased on the market. As can be seen from Table 1, 0.25% is a more desirable indicator, and the results show that the Bifidobacterium longum strain of the present invention has a significant advantage in adhesion.

TABLE 1 Bifidobacterium longum SF-B-27 adhesion Property test results

Bacterial strains	Number of remaining viable bacteria	Rate of adhesion
			Blank group	1×10⁹	100％
BB12	3×10⁶	0.3％
			SF-B-27	2×10⁶	0.25％
FB-01	1.5×10⁶	0.1％
			FB-02	3×10⁶	0.04％

Test example 2 Bifidobacterium longum SF-B-27 gastrointestinal tract suitability test

(1) Configuration of simulated gastric fluid: pepsin was dissolved in sterile physiological saline (0.9% w/v) and the pH was adjusted to 3.0 to a final concentration of 3 g/L. Filtering with 0.22 μm sterile filter membrane, and mixing;

(2) preparation of simulated intestinal fluid: trypsin was dissolved in sterilized normal saline (0.9% w/v, pH adjusted to 8.0) to a final concentration of 1g/L, and bile salt was added to a final concentration of 0.3%. Filtering with 0.22 μm sterile filter membrane, and mixing;

(3) the experiments were carried out after three successive generations (18 h each) of activation of different Lactobacillus plantarum (FB-01, FB-02 and SF-B-27). Measuring the OD value of the continuous activated third-generation strain under A600, and calculating the required amount of the OD 5;

(4) centrifuging the OD 5 bacterial liquid at 8000G for 10min, discarding the supernatant, suspending in 1mL simulated gastric juice, culturing at 37 deg.C for 3h, and counting viable bacteria on the plate;

(5) taking 8000G bacteria liquid treated by simulated gastric juice, centrifuging for 10min, discarding supernatant, suspending in simulated intestinal fluid with the same volume, culturing at 37 ℃ for 4h, and counting viable bacteria on a flat plate.

Survival after tolerating gastrointestinal fluids (%) × (number of viable bacteria in bacterial suspension after tolerating simulated intestinal fluids/number of original viable bacteria in bacterial suspension) x 100%.

TABLE 2 Bifidobacterium longum SF-B-27 gastrointestinal tract suitability test

Bacterial strain	Survival rate (%)
		Bifidobacterium longum FB-01	9.6
Bifidobacterium longum FB-02	8.9
		Bifidobacterium longum SF-B-27	16.5

The result shows that the bifidobacterium longum SF-B-27 has stronger gastrointestinal adaptability than other bifidobacterium longum.

Test example 3 improvement experiment of Bifidobacterium longum SF-B-27 on mouse sleep

90 healthy male mice (8 weeks old, 18-20g in weight) of SPF grade Balb-c were randomly divided into 3 groups of 30 mice each.

Control group: continuously irrigating the stomach with normal saline for 30 days;

test group 1: 0.02 g/body of a sleep improving product prepared in comparative example 1 was fed for 30 consecutive days

Test group 2: a product for improving sleep prepared in example 2 was fed for 30 consecutive days at a dose of 0.02 g/body

The test method comprises the following steps: the mouse is injected with pentobarbital sodium 0.2mL/20g through the abdominal cavity 20min after the test object is given at the last time, and whether the sample can prolong the sleep time of the pentobarbital sodium is observed by taking the disappearance of the righting reflex of the animal as an index. Blood is taken after a mouse is killed, the blood is placed for 1h to be coagulated, a centrifuge rotates at the rotating speed of 5000r/min for 10min to obtain serum, and the content of tryptophan and 5-hydroxytryptamine in the blood of the mouse is detected strictly according to the method of the specification of the ELISA detection kit for tryptophan and 5-hydroxytryptamine of the mouse.

And (3) test results: tryptophan plays an important role in the process of inducing sleep, and when free tryptophan in blood is carried by L-amino acid transport protein to pass through a blood brain barrier and enter the brain, the body can enter a sleep state by inducing and synthesizing 5-hydroxytryptamine. The result of prolonging the sleep time of sodium pentobarbital is shown in fig. 1, compared with the control group, the test group 2 and the test group 3 are obviously increased compared with the control group, and the test group 3 has more obvious effect than the test group 2. The contents of tryptophan and 5-hydroxytryptamine in the blood of the mice are respectively shown in fig. 2 and fig. 3, compared with the control group, the contents of tryptophan and 5-hydroxytryptamine in the blood of the mice in the test group 2 and the test group 3 are obviously increased compared with the control group, and the contents of tryptophan and 5-hydroxytryptamine in the blood of the mice in the test group 3 are obviously increased (P is less than 0.05) compared with.

According to the experimental results, the bifidobacterium longum SF-B-27 can obviously improve the sleep condition.

The present invention has been described in detail by way of preferred embodiments, but the present invention is not limited thereto. Various equivalent modifications or substitutions can be made on the embodiments of the present invention by those skilled in the art without departing from the spirit and scope of the present invention, and these modifications or substitutions are within the scope of the present invention/any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.

SEQUENCE LISTING

<110> Shandong sunflower bioengineering Co., Ltd

<120> lactobacillus longus SF-B-27 and application thereof

<130> 2020

<160> 3

<170> PatentIn version 3.3

<210> 1

<211> 1372

<212> DNA

<213> Lactobacillus longum (Bifidobacterium longum)

<400> 1

tggtgagagt ggcgaacggg tgagtaatgc gtgaccgacc tgccccatac accggaatag 60

ctcctggaaa cgggtggtaa tgccggatgc tccagttgat cgcatggtct tctgggaaag 120

ctttcgcggt atgggatggg gtcgcgtcct atcagcttga cggcggggta acggcccacc 180

gtggcttcga cgggtagccg gcctgagagg gcgaccggcc acattgggac tgagatacgg 240

cccagactcc tacgggaggc agcagtgggg aatattgcac aatgggcgca agcctgatgc 300

agcgacgccg cgtgagggat ggaggccttc gggttgtaaa cctcttttat cggggagcaa 360

gcgagagtga gtttacccgt tgaataagca ccggctaact acgtgccagc agccgcggta 420

atacgtaggg tgcaagcgtt atccggaatt attgggcgta aagggctcgt aggcggttcg 480

tcgcgtccgg tgtgaaagtc catcgcttaa cggtggatcc gcgccgggta cgggcgggct 540

tgagtgcggt aggggagact ggaattcccg gtgtaacggt ggaatgtgta gatatcggga 600

agaacaccaa tggcgaaggc aggtctctgg gccgttactg acgctgagga gcgaaaagcg 660

tggggagcga acaggattag ataccctggt agtccacgcc gtaacggtgg atgctggatg 720

tggggcccgt tccacgggtt ccgtgtcgga gctaacgcgt taagcatccc gcctggggag 780

tacggccgca aggctaaaac tcaaagaaat tgacgggggc ccgcacaagc ggcggagcat 840

gcggattaat tcgatgcaac gcgaagaacc ttacctgggc ttgacatgtt cccgacggtc 900

gtagagatac ggcttccctt cggggcgggt tcacaggtgg tgcatggtcg tcgtcagctc 960

gtgtcgtgag atgttgggtt aagtcccgca acgagcgcaa ccctcgcccc gtgttgccag 1020

cggattatgc cgggaactca cgggggaccg ccggggttaa ctcggaggaa ggtggggatg 1080

acgtcagatc atcatgcccc ttacgtccag ggcttcacgc atgctacaat ggccggtaca 1140

acgggatgcg acgcggcgac gcggagcgga tccctgaaaa ccggtctcag ttcggatcgc 1200

agtctgcaac tcgactgcgt gaaggcggag tcgctagtaa tcgcgaatca gcaacgtcgc 1260

ggtgaatgcg ttcccgggcc ttgtacacac cgcccgtcaa gtcatgaaag tgggcagcac 1320

ccgaagccgg tggcctaacc ccttgtggga tggagccgtc taaggtgagg ct 1372

<210> 2

<211> 20

<212> DNA

<213> Artificial Synthesis

<400> 2

agagtttgat cmtggctcag 20

<210> 3

<211> 19

<212> DNA

<213> Artificial Synthesis

<400> 3

ggttaccttg ttacgactt 19

Claims

1. The lactobacillus longus SF-B-27 is preserved in China general microbiological culture Collection center (CGMCC) No. 10 and No. 21 in 2020, and has the preservation number as follows: CGMCC No. 20925.

2. Use of lactobacillus longus SF-B-27 according to claim 1 for the preparation of a product for improving sleep.

3. A product for improving sleep, which comprises powder of Lactobacillus longus SF-B-27.

4. The product for improving sleep according to claim 3, wherein the powder of Lactobacillus bifidus SF-B-27 is prepared by: inoculating bifidobacterium longum SF-B-27 into an MRS liquid culture medium, wherein the inoculation amount is 1%, and after culturing at 37 ℃, centrifuging and carrying out vacuum freeze drying on MRS zymogen liquid to obtain bacterial powder.

5. The product for improving sleep as claimed in claim 3, wherein the content of Bifidobacterium longum SF-B-27 in the product is 100-500 hundred million/g.

6. The sleep-improving product according to claim 5, wherein the content of Bifidobacterium longum SF-B-27 in the product is 100, 200 or 500 hundred million/g.

7. The product for improving sleep according to claim 3, further comprising an auxiliary material, wherein the mass ratio of lactobacillus longus SF-B-27 to auxiliary material is 1: 100.

8. The product for improving sleep according to claim 7, wherein the auxiliary materials are any three or any five of red date, astragalus powder, codonopsis pilosula powder, gastrodia elata powder, isomaltooligosaccharide, fructo-oligosaccharide and wolfberry powder; wherein, isomaltooligosaccharide and fructo-oligosaccharide are not selected at the same time.

9. The product for improving sleep as claimed in claim 7, wherein the auxiliary materials are added in equal proportion by mass.